Roles
- Associate Professor of Clinical Medicine
-
Biography
Dr. Alejandra Perez received her medical degree from Instituto de Ciencias de la Salud (CES), completed her residency at Danbury Hospital – Yale University, and her fellowship at Montefiore Medical Center. She has a clinical interest in breast cancer prevention and treatment, and is board certified in both Medical Oncology and Internal Medicine. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
New Supportive Care Room Expands Cancer Survivorship Services in North Miami
Young Breast Cancer Survivor Finds Patient-First Care at Sylvester Comprehensive Cancer Center
A Mother’s Cancer Journey Inspires Her Daughter
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 14 clinical trials.
-
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens
- Principal Investigator: Alejandra Perez
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC.
- Principal Investigator: Alejandra Perez
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
- Principal Investigator: Alejandra Perez
- Study Phase: Phase 3
- Enrollment Status: Closed
-
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
- Principal Investigator: Alejandra Perez
- Study Phase: N/A
- Enrollment Status: Open
-
A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Principal Investigator: Alejandra Perez
- Study Phase: Phase 3
- Enrollment Status: Closed
-
The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve outcomes and delay the return of disease in patients with high-risk early TNBC when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine.
- Principal Investigator: Alejandra Perez
- Study Phase: Phase III
- Enrollment Status: Open
-
The purpose of this study is to see if therapy with camizestrant is better at preventing disease recurrence (disease that comes back) than standard endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen, the drugs that you and other patients with early ER+/HER2- breast cancer are currently receiving). Another drug, abemaciclib, could be added to camizestrant and to the endocrine therapy per your study doctors choice and according to local standard of care. We also want to better understand the studied disease and associated health problems.
- Principal Investigator: Alejandra Perez
- Study Phase: Phase III
- Enrollment Status: Not Accepting
-
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 sites worldwide.
- Principal Investigator: Alejandra Perez
- Study Phase: Phase III
- Enrollment Status: Closed
-
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
- Principal Investigator: Alejandra Perez
- Study Phase: Phase III
- Enrollment Status: Not Accepting
-
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
- Principal Investigator: Alejandra Perez
- Study Phase: Phase III
- Enrollment Status: Closed
-
We are doing this study because we want to find out if the immunotherapy and individualized vaccine is better or worse than the usual approach for your metastatic triple negative breast cancer. The usual approach for patients who are not in a study is treatment with chemotherapy alone. The purpose of this study is to compare any good and bad effects of using an individualized vaccine along with drugs called durvalumab and tremelimumab and standard chemotherapy to using durvalumab, tremelimumab, and standard chemotherapy alone.
- Principal Investigator: Alejandra Perez
- Study Phase: Phase II
- Enrollment Status: Open
-
A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)
- Principal Investigator: Alejandra Perez
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The purpose of this clinical study is to test the safety and efficacy of elacestrant compared to standard of care therapy in participants with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-) early breast cancer with high risk of coming back. To evaluate the effect of elacestrant compared to standard of care therapy in your ability to do your normal day to day activities. To assess what the study drug does to the tumor markers that can be measured in your blood that are related to development and growth of your tumor.
- Principal Investigator: Alejandra Perez
- Study Phase: Phase III
- Enrollment Status: Not Accepting
-
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
- Principal Investigator: Alejandra Perez
- Study Phase: Phase 3
- Enrollment Status: Closed
